<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00134719</url>
  </required_header>
  <id_info>
    <org_study_id>102370 (primary study)</org_study_id>
    <secondary_id>102371</secondary_id>
    <nct_id>NCT00134719</nct_id>
    <nct_alias>NCT00787046</nct_alias>
  </id_info>
  <brief_title>Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines</brief_title>
  <official_title>A Multicentre Primary &amp; Booster Vaccination Study of GSK Biologicals' Hib-MenCY-TT Conjugate Vaccine vs ActHIB® &amp; MenC Conjugate Licensed Vaccine When Given According to the 2-4-6 Month Schedule to Healthy Infants With Booster Dose at 12 to 15 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is evaluating the safety and immunogenicity of Hib-MenCY-TT vaccine compared to
      control groups receiving licensed Hib or MenC conjugate vaccines, each administered at 2, 4,
      6, and 12 to 15 months of age. Co-administration with live, attenuated measles, mumps, and
      rubella combination vaccine; and with live, attenuated varicella vaccine will be assessed
      with administration of the booster dose. The Protocol Posting has been updated in order to
      comply with the FDA Amendment Act, September 2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in 2 stages: a 3-dose primary vaccination at 2, 4 and 6 months of
      age and a booster vaccination at 12 to 15 months of age. All subjects will have 3 blood
      samples taken. Half of the subjects of each group will have a blood sample taken just prior
      to the administration of the third dose of the primary vaccination and the other half of the
      subjects of each group will have a blood sample taken at one month after the third vaccine
      dose of the primary vaccination phase. In addition, all subjects of all groups will have a
      blood sample taken before and 42 days after administration of the booster dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Concentration Greater Than or Equal to 1.0 Microgram Per Milliliter (µg/mL)</measure>
    <time_frame>One month after the 3-dose primary vaccination course</time_frame>
    <description>The analysis was performed on blood samples taken from half of the subjects in the MenHibrix and ActHIB/PedvaxHib groups only. The other half of the subjects in these study groups donated a blood sample after the second vaccine dose for analysis of the corresponding secondary outcome measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Meningococcal Polysaccharide C Serum Bactericidal Activity/Assay Using Baby Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to 1:128</measure>
    <time_frame>One month after the 3-dose primary vaccination course</time_frame>
    <description>The analysis was performed on blood samples taken from half of the subjects in the MenHibrix and ActHIB + Meningitec groups only. The other half of the subjects in these study groups donated a blood sample after the second vaccine dose for analysis of the corresponding secondary outcome measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-measles Antibodies</measure>
    <time_frame>42 days after the fourth dose vaccination</time_frame>
    <description>The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-measles seroconversion is defined as the appearance of antibodies (i.e. concentration greater than or equal to the cut-off value of 150 milli-international units per milliliter (mIU/mL)) in the serum of subjects seronegative (below 150 mIU/mL) before vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-mumps Antibodies</measure>
    <time_frame>42 days after the fourth dose vaccination</time_frame>
    <description>The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-mumps seroconversion is defined as titer greater than or equal to 28 ED50 in subjects seronegative (&lt;28 ED50) before vaccination.
ED50 is defined as the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With an Anti-rubella Seroresponse</measure>
    <time_frame>42 days after the fourth dose vaccination</time_frame>
    <description>The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-rubella seroresponse is defined as post-vaccination concentration greater than or equal to 10 IU/mL (ELISA, Enzygnost) in subjects seronegative (concentration below 4 IU/mL) before vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-varicella Antibodies</measure>
    <time_frame>42 days after the fourth dose vaccination</time_frame>
    <description>The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-varicella seroconversion is defined as post-vaccination titers greater than or equal to 1:5, in subjects seronegative (titers below 1:5) before vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With rSBA-MenC Titer Greater Than or Equal to Pre-defined Cut-off Values</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were titers 1:8 and 1:128.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rSBA-MenC Titers</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. Titers are given as Geometric Mean Titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With rSBA-MenY Titer Greater Than or Equal to Pre-defined Cut-off Values</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were titers 1:8 and 1:128.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rSBA-MenY Titers</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. Titers are given as Geometric Mean Titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Meningococcal Polysaccharide C Serum Bactericidal Activity/Assay Using Human Complement (hSBA-MenC) Antibody Titer Greater Than or Equal to Pre-defined Cut-off Values</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analysis for was performed on the first 30% of the blood samples taken at each time point. The cut-off values assessed were titers 1:4 and 1:8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA-MenC Titers</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analysis for was performed on the first 30% of the blood samples taken at each time point. Titers are given as Geometric Mean Titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Meningococcal Polysaccharide Y Serum Bactericidal Activity/Assay Using Human Complement (hSBA-MenY) Antibody Titer Greater Than or Equal to Pre-defined Cut-off Values</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analysis for was performed on the first 30% of the blood samples taken at each time point. The cut-off values assessed were titers 1:4 and 1:8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA-MenY Titers</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analysis for was performed on the first 30% of the blood samples taken at each time point. Titers are given as Geometric Mean Titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-Polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were 0.3 µg/mL and 2 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PSC Concentrations</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. Concentrations are given as Geometric Mean Concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-Polysaccharide Y (Anti-PSY) Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were 0.3 µg/mL and 2 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PSY Concentrations</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. Concentrations are given as Geometric Mean Concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-PRP Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were 0.15 µg/mL and 1.0 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PRP Concentrations</measure>
    <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
    <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. Concentrations are given as Geometric Mean Concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-measles Concentration Greater Than or Equal to 150 mIU/mL</measure>
    <time_frame>Just prior to the fourth dose and 42 days after the fourth dose</time_frame>
    <description>The cut-off value assessed was 150 mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-mumps Titer Greater Than or Equal to 24 ED50</measure>
    <time_frame>Just prior to the fourth dose and 42 days after the fourth dose</time_frame>
    <description>ED50 is defined as the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-rubella Concentration Greater Than or Equal to 4 IU/mL</measure>
    <time_frame>Just prior to the fourth dose and 42 days after the fourth dose</time_frame>
    <description>The cut-off value assessed was 4 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-varicella Titer Greater Than or Equal to 1:5</measure>
    <time_frame>Just prior to the fourth dose and 42 days after the fourth dose</time_frame>
    <description>The cut-off value assessed was a titer of 1:5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Fourth Dose Response for hSBA-MenC</measure>
    <time_frame>42 days after the fourth dose</time_frame>
    <description>Fourth dose response for hSBA-MenC is defined as: •For initially seronegative subjects (i.e., subjects with pre fourth dose hSBA antibody titer below 1:4), post fourth dose hSBA antibody titer greater than or equal to 1:16; •For initially seropositive subjects (i.e., subjects with pre fourth dose antibody titer greater than or equal to 1:4), post fourth dose hSBA antibody titer greater than or equal to 1:128.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Fourth Dose Response for hSBA-MenY</measure>
    <time_frame>42 days after the fourth dose</time_frame>
    <description>Fourth dose response for hSBA-MenY defined as: •For initially seronegative subjects (i.e., pre fourth dose hSBA antibody titer &lt; 1:4), post fourth dose hSBA antibody titer greater than or equal to (≥) 1:16; •For initially seropositive subjects with pre fourth dose hSBA antibody titer ≥ 1:4 and &lt; 1:64, post fourth dose hSBA antibody titer at least 4-fold higher than the pre fourth dose hSBA antibody titer; •For initially seropositive subjects with pre fourth dose hSBA antibody titer ≥ 1:64, post fourth dose hSBA antibody titer at least 2-fold higher than the pre fourth dose hSBA antibody titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-measles Concentration Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects</measure>
    <time_frame>42 days after the fourth dose</time_frame>
    <description>The pre-defined cut-off values were 150 mIU/mL and 200 mIU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-measles concentration below 150 mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-measles Concentrations in Initially Seronegative Subjects</measure>
    <time_frame>42 days after the fourth dose</time_frame>
    <description>Concentrations are presented as Geometric Mean Concentrations expressed as mIU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-measles concentration below 150 mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-rubella Concentration Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects</measure>
    <time_frame>42 days after the fourth dose</time_frame>
    <description>The pre-defined cut-off values were 4 IU/mL and 10 IU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-measles concentration below 4 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-rubella Concentrations in Initially Seronegative Subjects</measure>
    <time_frame>42 days after the fourth dose</time_frame>
    <description>Concentrations are presented as Geometric Mean Concentrations expressed as IU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-rubella concentration below 4 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-mumps Titer Greater Than or Equal to 28 ED50 in Subjects With Anti-mumps Titer Below 28 ED50 Before Vaccination</measure>
    <time_frame>42 days after the fourth dose</time_frame>
    <description>ED50 is defined as the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-mumps Titer Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects</measure>
    <time_frame>42 days after the fourth dose</time_frame>
    <description>The pre-defined cut-off values were 28 ED50 and 51 ED50. Initially seronegative subjects are defined as subjects with pre-vaccination anti-mumps titer below 24 ED50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-mumps Titers in Initially Seronegative Subjects</measure>
    <time_frame>42 days after the fourth dose</time_frame>
    <description>Titers are presented as Geometric Mean Titers expressed as ED50, the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent. Initially seronegative subjects are defined as subjects with pre-vaccination anti-mumps titer below 24 ED50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-varicella Titer Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects</measure>
    <time_frame>42 days after the fourth dose</time_frame>
    <description>The pre-defined cut-off values were 1:5 and 1:40. Initially seronegative subjects are defined as subjects with pre-vaccination anti-varicella titer below 1:5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-varicella Titers in Initially Seronegative Subjects</measure>
    <time_frame>42 days after the fourth dose</time_frame>
    <description>Titers are presented as Geometric Mean Titers. Initially seronegative subjects are defined as subjects with pre-vaccination anti-varicella titer below 1:5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and General Symptoms During the Primary Vaccination Phase</measure>
    <time_frame>During a 4-day period (Day 0-3) after any vaccine dose in the primary vaccination phase</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever (rectal temperature greater than or equal to 38 degrees Celcius), irritability and loss of appetite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and General Symptoms During the Fourth Dose Vaccination Phase</measure>
    <time_frame>During a 4-day period (Day 0-3) after the fourth dose vaccination phase</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever (rectal temperature greater than or equal to 38 degrees Celcius), irritability and loss of appetite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events</measure>
    <time_frame>During the 31-day (Day 0-30) post-primary and post-fourth dose vaccination period</time_frame>
    <description>Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Specific Solicited General AEs Related to Measles, Mumps, Rubella Vaccine and Varicella Vaccine</measure>
    <time_frame>During a 43-day (Day 0-42) after the fourth dose</time_frame>
    <description>Specific solicited general symptoms assessed include fever (temperature greater than or equal to 38 degrees Celcius), meningismus/ febrile convulsion, parotid / salivary gland swelling and rash.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs), New Onset of Chronic Illnesses (NOCI), Rash, Emergency Room Visits (ER), Physician Office Visits (PO) During the Primary Vaccination Phase</measure>
    <time_frame>From enrolment through the day preceding the fourth dose</time_frame>
    <description>SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. NOCI: e.g. autoimmune disorders, asthma, type I diabetes and allergies. Types of rash: hives, idiopathic thrombocytopenic purpura and petechiae. ER and PO visits assessed were not related to well-child care, vaccination, injury or common acute illnesses such as upper respiratory tract infection, otitis media, pharyngitis and gastroenteritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs), New Onset of Chronic Illnesses (NOCI), Rash, Emergency Room Visits (ER), Physician Office Visits (PO) During the Fourth Dose Vaccination Phase</measure>
    <time_frame>From the day of administration of the fourth dose until the end of the extended safety follow-up period (last study contact at 18-21 months of age</time_frame>
    <description>SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. NOCI: e.g. autoimmune disorders, asthma, type I diabetes and allergies. Types of rash: hives, idiopathic thrombocytopenic purpura and petechiae. ER and PO visits assessed were not related to well-child care, vaccination, injury or common acute illnesses such as upper respiratory tract infection, otitis media, pharyngitis and gastroenteritis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1104</enrollment>
  <condition>Neisseria Meningitidis</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <arm_group>
    <arm_group_label>MenHibrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ActHIB + Meningitec Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ActHIB/PedvaxHIB Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenHibrix (Hib-MenCY-TT)</intervention_name>
    <description>One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)</description>
    <arm_group_label>ActHIB + Meningitec Group</arm_group_label>
    <arm_group_label>MenHibrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix® Penta</intervention_name>
    <description>One intramuscular dose at 2, 4 and 6 months of age</description>
    <arm_group_label>ActHIB + Meningitec Group</arm_group_label>
    <arm_group_label>ActHIB/PedvaxHIB Group</arm_group_label>
    <arm_group_label>MenHibrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar®</intervention_name>
    <description>One intramuscular dose at 2, 4 and 6 months of age</description>
    <arm_group_label>ActHIB + Meningitec Group</arm_group_label>
    <arm_group_label>ActHIB/PedvaxHIB Group</arm_group_label>
    <arm_group_label>MenHibrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ActHIB®</intervention_name>
    <description>One intramuscular dose at 2, 4 and 6 months of age</description>
    <arm_group_label>ActHIB + Meningitec Group</arm_group_label>
    <arm_group_label>ActHIB/PedvaxHIB Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningitec®</intervention_name>
    <description>One intramuscular dose at 2, 4 and 6 months of age</description>
    <arm_group_label>ActHIB + Meningitec Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M-M-R®II</intervention_name>
    <description>One subcutaneous dose at 12-15 months of age</description>
    <arm_group_label>ActHIB + Meningitec Group</arm_group_label>
    <arm_group_label>ActHIB/PedvaxHIB Group</arm_group_label>
    <arm_group_label>MenHibrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Varivax®</intervention_name>
    <description>One subcutaneous dose at 12 to 15 months of age</description>
    <arm_group_label>ActHIB + Meningitec Group</arm_group_label>
    <arm_group_label>ActHIB/PedvaxHIB Group</arm_group_label>
    <arm_group_label>MenHibrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PedvaxHIB®</intervention_name>
    <description>One intramuscular dose at 12 to 15 months of age</description>
    <arm_group_label>ActHIB/PedvaxHIB Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects for whom the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol should be enrolled in the study.

          -  A male or female between, and including, 6 and 12 weeks of age at the time of the
             first vaccination.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Born after a gestation period between 36 and 42 weeks.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs since birth.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             within 30 days of the first dose of vaccine(s).

          -  Previous vaccination against Neisseria meningitidis, Haemophilus influenzae type b,
             diphtheria, tetanus, pertussis, poliovirus, and/or Streptococcus pneumoniae; more than
             one previous dose of hepatitis B vaccine. Vaccination with hepatitis B at birth is
             accepted (although not mandatory). Influenza vaccination is allowed 30 days after
             administration of the third vaccine dose to 30 days preceding the booster dose.

          -  History of Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus,
             pertussis, hepatitis B, poliovirus, Streptococcus pneumoniae and/or varicella invasive
             disease.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine(s), including dry natural latex rubber, tetanus toxoid, diphtheria toxoid,
             neomycin, polymyxin.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.

          -  Additional specific criteria for the booster part of the study

          -  History of or previous vaccination against measles, mumps, rubella or varicella.

          -  Previous booster vaccination with Hib or meningococcal serogroup C vaccine since the
             last visit of the primary phase.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Bryant KA, Marshall GS. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Expert Rev Vaccines. 2011 Jul;10(7):941-50. doi: 10.1586/erv.11.90. Review.</citation>
    <PMID>21806393</PMID>
  </reference>
  <reference>
    <citation>Bryant K, McVernon J, Marchant C, Nolan T, Marshall G, Richmond P, Marshall H, Nissen M, Lambert S, Aris E, Mesaros N, Miller J. Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials. Hum Vaccin Immunother. 2012 Aug;8(8):1036-41. doi: 10.4161/hv.20357. Epub 2012 Aug 1.</citation>
    <PMID>22617844</PMID>
  </reference>
  <reference>
    <citation>Nolan T, Richmond P, Marshall H, McVernon J, Alexander K, Mesaros N, Aris E, Miller J, Poolman J, Boutriau D. Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J. 2011 Mar;30(3):190-6. doi: 10.1097/INF.0b013e3181fcb2bf.</citation>
    <PMID>20948453</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2005</study_first_posted>
  <results_first_submitted>June 15, 2012</results_first_submitted>
  <results_first_submitted_qc>June 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2012</results_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Invasive Hib &amp; N. meningitidis diseases</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>102370 (primary study)</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102370 (primary study)</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102370 (primary study)</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102370 (primary study)</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register. The results of this study 102370 are summarised with study 102371 on the GSK Clinical Study Register.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102370 (primary study)</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were randomised at the beginning of the primary vaccination phase and kept their group assignment during the fourth dose vaccination phase. Not all subjects who completed the primary vaccination phase returned for participation in the fourth dose vaccination phase.</recruitment_details>
      <pre_assignment_details>One subject who had a subject number allocated, was not vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenHibrix Group</title>
          <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
        </group>
        <group group_id="P2">
          <title>ActHIB + Meningitec Group</title>
          <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
        </group>
        <group group_id="P3">
          <title>ActHIB/PedvaxHIB Group</title>
          <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Vaccination Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="661"/>
                <participants group_id="P2" count="221"/>
                <participants group_id="P3" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="647"/>
                <participants group_id="P2" count="215"/>
                <participants group_id="P3" count="216"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Fourth Dose Vaccination Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="625"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="623"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mother just delivered a new baby</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MenHibrix Group</title>
          <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
        </group>
        <group group_id="B2">
          <title>ActHIB + Meningitec Group</title>
          <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
        </group>
        <group group_id="B3">
          <title>ActHIB/PedvaxHIB Group</title>
          <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="661"/>
            <count group_id="B2" value="221"/>
            <count group_id="B3" value="221"/>
            <count group_id="B4" value="1103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" spread="7.38"/>
                    <measurement group_id="B2" value="61.5" spread="7.22"/>
                    <measurement group_id="B3" value="61.5" spread="7.95"/>
                    <measurement group_id="B4" value="61.2" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="328"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="333"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Concentration Greater Than or Equal to 1.0 Microgram Per Milliliter (µg/mL)</title>
        <description>The analysis was performed on blood samples taken from half of the subjects in the MenHibrix and ActHIB/PedvaxHib groups only. The other half of the subjects in these study groups donated a blood sample after the second vaccine dose for analysis of the corresponding secondary outcome measure.</description>
        <time_frame>One month after the 3-dose primary vaccination course</time_frame>
        <population>Analysis was performed on half of the subjects in the MenHibrix and ActHIB/PedvaxHib groups only, on the Primary According-to-Protocol (ATP) Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Concentration Greater Than or Equal to 1.0 Microgram Per Milliliter (µg/mL)</title>
          <description>The analysis was performed on blood samples taken from half of the subjects in the MenHibrix and ActHIB/PedvaxHib groups only. The other half of the subjects in these study groups donated a blood sample after the second vaccine dose for analysis of the corresponding secondary outcome measure.</description>
          <population>Analysis was performed on half of the subjects in the MenHibrix and ActHIB/PedvaxHib groups only, on the Primary According-to-Protocol (ATP) Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Meningococcal Polysaccharide C Serum Bactericidal Activity/Assay Using Baby Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to 1:128</title>
        <description>The analysis was performed on blood samples taken from half of the subjects in the MenHibrix and ActHIB + Meningitec groups only. The other half of the subjects in these study groups donated a blood sample after the second vaccine dose for analysis of the corresponding secondary outcome measure.</description>
        <time_frame>One month after the 3-dose primary vaccination course</time_frame>
        <population>Analysis was performed on subjects in the MenHibrix and ActHIB + Meningitec groups only, on the Primary According-to-Protocol Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Meningococcal Polysaccharide C Serum Bactericidal Activity/Assay Using Baby Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to 1:128</title>
          <description>The analysis was performed on blood samples taken from half of the subjects in the MenHibrix and ActHIB + Meningitec groups only. The other half of the subjects in these study groups donated a blood sample after the second vaccine dose for analysis of the corresponding secondary outcome measure.</description>
          <population>Analysis was performed on subjects in the MenHibrix and ActHIB + Meningitec groups only, on the Primary According-to-Protocol Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroconverted for Anti-measles Antibodies</title>
        <description>The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-measles seroconversion is defined as the appearance of antibodies (i.e. concentration greater than or equal to the cut-off value of 150 milli-international units per milliliter (mIU/mL)) in the serum of subjects seronegative (below 150 mIU/mL) before vaccination.</description>
        <time_frame>42 days after the fourth dose vaccination</time_frame>
        <population>Analysis was performed on initially seronegative subjects in the MenHibrix and ActHIB groups only, on the Fourth dose According-to-Protocol cohort for immunogenicity, including all evaluable subjects with assay result available for the blood sample taken at 42 days after the administration of the fourth vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Anti-measles Antibodies</title>
          <description>The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-measles seroconversion is defined as the appearance of antibodies (i.e. concentration greater than or equal to the cut-off value of 150 milli-international units per milliliter (mIU/mL)) in the serum of subjects seronegative (below 150 mIU/mL) before vaccination.</description>
          <population>Analysis was performed on initially seronegative subjects in the MenHibrix and ActHIB groups only, on the Fourth dose According-to-Protocol cohort for immunogenicity, including all evaluable subjects with assay result available for the blood sample taken at 42 days after the administration of the fourth vaccine dose.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="852"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="815"/>
                    <measurement group_id="O3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroconverted for Anti-mumps Antibodies</title>
        <description>The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-mumps seroconversion is defined as titer greater than or equal to 28 ED50 in subjects seronegative (&lt;28 ED50) before vaccination.
ED50 is defined as the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent.</description>
        <time_frame>42 days after the fourth dose vaccination</time_frame>
        <population>Analysis was performed on initially seronegative subjects in the MenHibrix and ActHIB groups only, on the Fourth dose According-to-Protocol cohort for immunogenicity, including all evaluable subjects with assay result available for the blood sample taken at 42 days after the administration of the fourth vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Anti-mumps Antibodies</title>
          <description>The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-mumps seroconversion is defined as titer greater than or equal to 28 ED50 in subjects seronegative (&lt;28 ED50) before vaccination.
ED50 is defined as the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent.</description>
          <population>Analysis was performed on initially seronegative subjects in the MenHibrix and ActHIB groups only, on the Fourth dose According-to-Protocol cohort for immunogenicity, including all evaluable subjects with assay result available for the blood sample taken at 42 days after the administration of the fourth vaccine dose.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="595"/>
                    <measurement group_id="O3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With an Anti-rubella Seroresponse</title>
        <description>The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-rubella seroresponse is defined as post-vaccination concentration greater than or equal to 10 IU/mL (ELISA, Enzygnost) in subjects seronegative (concentration below 4 IU/mL) before vaccination.</description>
        <time_frame>42 days after the fourth dose vaccination</time_frame>
        <population>Analysis was performed on initially seronegative subjects in the MenHibrix and ActHIB groups only, on the Fourth dose According-to-Protocol cohort for immunogenicity, including all evaluable subjects with assay result available for the blood sample taken at 42 days after the administration of the fourth vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an Anti-rubella Seroresponse</title>
          <description>The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-rubella seroresponse is defined as post-vaccination concentration greater than or equal to 10 IU/mL (ELISA, Enzygnost) in subjects seronegative (concentration below 4 IU/mL) before vaccination.</description>
          <population>Analysis was performed on initially seronegative subjects in the MenHibrix and ActHIB groups only, on the Fourth dose According-to-Protocol cohort for immunogenicity, including all evaluable subjects with assay result available for the blood sample taken at 42 days after the administration of the fourth vaccine dose.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="850"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="848"/>
                    <measurement group_id="O3" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroconverted for Anti-varicella Antibodies</title>
        <description>The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-varicella seroconversion is defined as post-vaccination titers greater than or equal to 1:5, in subjects seronegative (titers below 1:5) before vaccination.</description>
        <time_frame>42 days after the fourth dose vaccination</time_frame>
        <population>Analysis was performed on initially seronegative subjects in the MenHibrix and ActHIB groups only, on the Fourth dose According-to-Protocol cohort for immunogenicity, including all evaluable subjects with assay result available for the blood sample taken at 42 days after the administration of the fourth vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Anti-varicella Antibodies</title>
          <description>The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-varicella seroconversion is defined as post-vaccination titers greater than or equal to 1:5, in subjects seronegative (titers below 1:5) before vaccination.</description>
          <population>Analysis was performed on initially seronegative subjects in the MenHibrix and ActHIB groups only, on the Fourth dose According-to-Protocol cohort for immunogenicity, including all evaluable subjects with assay result available for the blood sample taken at 42 days after the administration of the fourth vaccine dose.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="723"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="722"/>
                    <measurement group_id="O3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With rSBA-MenC Titer Greater Than or Equal to Pre-defined Cut-off Values</title>
        <description>The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were titers 1:8 and 1:128.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With rSBA-MenC Titer Greater Than or Equal to Pre-defined Cut-off Values</title>
          <description>The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were titers 1:8 and 1:128.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="496"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 titer ≥ 1:8 (N=295; 100; 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 titer ≥ 1:8 (N=287; 99; 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 titer ≥ 1:8 (N=495; 169; 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449"/>
                    <measurement group_id="O2" value="143"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 titer ≥ 1:8 (N=496; 162; 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 2 titer ≥ 1:128 (N=295; 100; 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 titer ≥ 1:128 (N=287; 99; 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 titer ≥ 1:128 (N=495; 169; 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 titer ≥ 1:128 (N=496; 162; 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="482"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>rSBA-MenC Titers</title>
        <description>The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. Titers are given as Geometric Mean Titers.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>rSBA-MenC Titers</title>
          <description>The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. Titers are given as Geometric Mean Titers.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="496"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 (N=295; 100; 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356.9" lower_limit="302.6" upper_limit="420.9"/>
                    <measurement group_id="O2" value="714.5" lower_limit="541.6" upper_limit="942.7"/>
                    <measurement group_id="O3" value="4.2" lower_limit="3.9" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 (N=287; 99; 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="804.6" lower_limit="699.9" upper_limit="924.9"/>
                    <measurement group_id="O2" value="790.1" lower_limit="649.4" upper_limit="961.2"/>
                    <measurement group_id="O3" value="4.5" lower_limit="4.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 (N=495; 169; 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.8" lower_limit="90.1" upper_limit="117.3"/>
                    <measurement group_id="O2" value="53.7" lower_limit="43.0" upper_limit="67.1"/>
                    <measurement group_id="O3" value="5.2" lower_limit="4.6" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 (N=496; 162; 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1696.7" lower_limit="1515.8" upper_limit="1899.2"/>
                    <measurement group_id="O2" value="261.9" lower_limit="204.4" upper_limit="335.7"/>
                    <measurement group_id="O3" value="5.4" lower_limit="4.7" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With rSBA-MenY Titer Greater Than or Equal to Pre-defined Cut-off Values</title>
        <description>The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were titers 1:8 and 1:128.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With rSBA-MenY Titer Greater Than or Equal to Pre-defined Cut-off Values</title>
          <description>The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were titers 1:8 and 1:128.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 titer ≥ 1:8 (N=293; 99; 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 titer ≥ 1:8 (N=288; 98; 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 titer ≥ 1:8 (N= 514; 167; 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="506"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 titer ≥ 1:8 (N=496; 164; 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="496"/>
                    <measurement group_id="O2" value="162"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 2 titer ≥ 1:128 (N= 293; 99; 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 titer ≥ 1:128 (N= 288; 98; 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 titer ≥ 1:128 (N= 514; 167; 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 titer ≥ 1:128 (N=496; 164; 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>rSBA-MenY Titers</title>
        <description>The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. Titers are given as Geometric Mean Titers.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>rSBA-MenY Titers</title>
          <description>The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. Titers are given as Geometric Mean Titers.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 (N=293; 99; 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.6" lower_limit="271.6" upper_limit="366.9"/>
                    <measurement group_id="O2" value="5.4" lower_limit="4.5" upper_limit="6.5"/>
                    <measurement group_id="O3" value="5.9" lower_limit="4.7" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 (N=288; 98; 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="728.3" lower_limit="635.5" upper_limit="834.7"/>
                    <measurement group_id="O2" value="7.1" lower_limit="5.4" upper_limit="9.3"/>
                    <measurement group_id="O3" value="7.7" lower_limit="5.9" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 (N= 514; 167; 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.4" lower_limit="240.7" upper_limit="290.4"/>
                    <measurement group_id="O2" value="16.0" lower_limit="12.0" upper_limit="21.2"/>
                    <measurement group_id="O3" value="10.5" lower_limit="8.0" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 (N=496; 164; 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1986.5" lower_limit="1825.9" upper_limit="2161.3"/>
                    <measurement group_id="O2" value="797.7" lower_limit="658.5" upper_limit="966.2"/>
                    <measurement group_id="O3" value="34.4" lower_limit="25.2" upper_limit="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Meningococcal Polysaccharide C Serum Bactericidal Activity/Assay Using Human Complement (hSBA-MenC) Antibody Titer Greater Than or Equal to Pre-defined Cut-off Values</title>
        <description>The analysis for was performed on the first 30% of the blood samples taken at each time point. The cut-off values assessed were titers 1:4 and 1:8.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Meningococcal Polysaccharide C Serum Bactericidal Activity/Assay Using Human Complement (hSBA-MenC) Antibody Titer Greater Than or Equal to Pre-defined Cut-off Values</title>
          <description>The analysis for was performed on the first 30% of the blood samples taken at each time point. The cut-off values assessed were titers 1:4 and 1:8.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 titer ≥ 1:4 (N= 89; 31; 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 titer ≥ 1:4 (N= 83; 28; 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 titer ≥ 1:4 (N= 134; 54; 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 titer ≥ 1:4 (N= 132; 43; 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 2 titer ≥ 1:8 (N= 89; 31; 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 titer ≥ 1:8 (N= 83; 28; 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 titer ≥ 1:8 (N= 134; 54; 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 titer ≥ 1:8 (N= 132; 43; 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA-MenC Titers</title>
        <description>The analysis for was performed on the first 30% of the blood samples taken at each time point. Titers are given as Geometric Mean Titers.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA-MenC Titers</title>
          <description>The analysis for was performed on the first 30% of the blood samples taken at each time point. Titers are given as Geometric Mean Titers.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 (N= 89; 31; 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.4" lower_limit="130.3" upper_limit="247.1"/>
                    <measurement group_id="O2" value="319.0" lower_limit="173.6" upper_limit="586.2"/>
                    <measurement group_id="O3" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 (N= 83; 28; 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.4" lower_limit="294.6" upper_limit="488.6"/>
                    <measurement group_id="O2" value="254.2" lower_limit="192.7" upper_limit="335.4"/>
                    <measurement group_id="O3" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 (N= 134; 54; 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="74.0" upper_limit="128.9"/>
                    <measurement group_id="O2" value="34.6" lower_limit="22.8" upper_limit="52.6"/>
                    <measurement group_id="O3" value="2.6" lower_limit="2.0" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 (N= 132; 43; 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1807.6" lower_limit="1398.2" upper_limit="2336.8"/>
                    <measurement group_id="O2" value="171.5" lower_limit="94.7" upper_limit="310.8"/>
                    <measurement group_id="O3" value="2.2" lower_limit="1.8" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Meningococcal Polysaccharide Y Serum Bactericidal Activity/Assay Using Human Complement (hSBA-MenY) Antibody Titer Greater Than or Equal to Pre-defined Cut-off Values</title>
        <description>The analysis for was performed on the first 30% of the blood samples taken at each time point. The cut-off values assessed were titers 1:4 and 1:8.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Meningococcal Polysaccharide Y Serum Bactericidal Activity/Assay Using Human Complement (hSBA-MenY) Antibody Titer Greater Than or Equal to Pre-defined Cut-off Values</title>
          <description>The analysis for was performed on the first 30% of the blood samples taken at each time point. The cut-off values assessed were titers 1:4 and 1:8.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 titer ≥ 1:4 (N= 88; 31; 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 titer ≥ 1:4 (N= 85; 28; 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 titer ≥ 1:4 (N= 114; 44; 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 titer ≥ 1:4 (N= 122; 34; 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 2 titer ≥ 1:8 (N= 88; 31; 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 titer ≥ 1:8 (N= 85; 28; 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 titer ≥ 1:8 (N= 114; 44; 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 titer ≥ 1:8 (N= 122; 34; 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA-MenY Titers</title>
        <description>The analysis for was performed on the first 30% of the blood samples taken at each time point. Titers are given as Geometric Mean Titers.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA-MenY Titers</title>
          <description>The analysis for was performed on the first 30% of the blood samples taken at each time point. Titers are given as Geometric Mean Titers.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 (N= 88; 31; 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="19.3" upper_limit="34.1"/>
                    <measurement group_id="O2" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 (N= 85; 28; 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="68.9" upper_limit="108.3"/>
                    <measurement group_id="O2" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 (N= 114; 44; 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" lower_limit="58.6" upper_limit="112.6"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.8" upper_limit="2.7"/>
                    <measurement group_id="O3" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 (N= 122; 34; 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1002.2" lower_limit="740.9" upper_limit="1355.7"/>
                    <measurement group_id="O2" value="8.8" lower_limit="4.4" upper_limit="17.3"/>
                    <measurement group_id="O3" value="18.3" lower_limit="7.7" upper_limit="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-Polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values</title>
        <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were 0.3 µg/mL and 2 µg/mL.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-Polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values</title>
          <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were 0.3 µg/mL and 2 µg/mL.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 concentration ≥0.3 µg/mL (N=296;95;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 concentration ≥0.3 µg/mL (N=276;95;91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 concentration≥0.3 µg/mL (N=475;160;138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 concentration≥0.3µg/mL (N=490;160;122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489"/>
                    <measurement group_id="O2" value="158"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 2 concentration ≥2.0 µg/mL (N=296;95;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 concentration ≥2.0 µg/mL (N=276;95;91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 concentration≥2.0 µg/mL (N=475;160;138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 concentration≥2.0µg/mL (N=490;160;122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PSC Concentrations</title>
        <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. Concentrations are given as Geometric Mean Concentrations.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PSC Concentrations</title>
          <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. Concentrations are given as Geometric Mean Concentrations.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Microgram per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 (N= 296; 95; 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" lower_limit="3.98" upper_limit="4.69"/>
                    <measurement group_id="O2" value="3.54" lower_limit="3.08" upper_limit="4.06"/>
                    <measurement group_id="O3" value="0.17" lower_limit="0.15" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 (N= 276; 95; 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" lower_limit="3.87" upper_limit="4.46"/>
                    <measurement group_id="O2" value="3.94" lower_limit="3.40" upper_limit="4.55"/>
                    <measurement group_id="O3" value="0.16" lower_limit="0.15" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 (N= 475; 160; 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.71" upper_limit="0.83"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.73" upper_limit="1.01"/>
                    <measurement group_id="O3" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 (N= 490; 160; 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" lower_limit="4.42" upper_limit="5.16"/>
                    <measurement group_id="O2" value="2.65" lower_limit="2.24" upper_limit="3.14"/>
                    <measurement group_id="O3" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-Polysaccharide Y (Anti-PSY) Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values</title>
        <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were 0.3 µg/mL and 2 µg/mL.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-Polysaccharide Y (Anti-PSY) Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values</title>
          <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were 0.3 µg/mL and 2 µg/mL.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 concentration ≥0.3 µg/mL (N=291;92;83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 concentration ≥0.3 µg/mL (N=269;91;88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 concentration≥0.3 µg/mL (N=474;136;112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="469"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 concentration≥0.3µg/mL (N=502;162;122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="502"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 2 concentration ≥2.0 µg/mL (N=291;92;83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 concentration ≥2.0 µg/mL (N=269;91;88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 concentration≥2.0 µg/mL (N=474;136;112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 concentration≥2.0µg/mL (N=502;162;122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PSY Concentrations</title>
        <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. Concentrations are given as Geometric Mean Concentrations.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PSY Concentrations</title>
          <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. Concentrations are given as Geometric Mean Concentrations.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Microgram per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 (N= 291; 92; 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.81" lower_limit="7.04" upper_limit="8.67"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.15" upper_limit="0.16"/>
                    <measurement group_id="O3" value="0.17" lower_limit="0.15" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 (N= 269; 91; 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.92" lower_limit="11.80" upper_limit="14.14"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                    <measurement group_id="O3" value="0.16" lower_limit="0.15" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 (N= 474; 136; 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" lower_limit="2.26" upper_limit="2.64"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.15" upper_limit="0.16"/>
                    <measurement group_id="O3" value="0.16" lower_limit="0.15" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 (N= 502; 162; 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.92" lower_limit="15.60" upper_limit="18.35"/>
                    <measurement group_id="O2" value="7.09" lower_limit="6.05" upper_limit="8.31"/>
                    <measurement group_id="O3" value="0.16" lower_limit="0.15" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-PRP Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values</title>
        <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were 0.15 µg/mL and 1.0 µg/mL.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-PRP Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values</title>
          <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were 0.15 µg/mL and 1.0 µg/mL.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 ≥ 0.15 µg/mL (N= 280; 94; 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 ≥ 0.15 µg/mL (N= 265; 88; 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 ≥ 0.15 µg/mL (N= 562; 189; 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 ≥ 0.15 µg/mL (N= 549; 185; 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="549"/>
                    <measurement group_id="O2" value="183"/>
                    <measurement group_id="O3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 2 ≥ 1.0 µg/mL (N= 280; 94; 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 ≥ 1.0 µg/mL (N= 265; 88; 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 ≥ 1.0 µg/mL (N= 562; 189; 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 ≥ 1.0 µg/mL (N= 549; 185; 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="547"/>
                    <measurement group_id="O2" value="176"/>
                    <measurement group_id="O3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PRP Concentrations</title>
        <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. Concentrations are given as Geometric Mean Concentrations.</description>
        <time_frame>After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4)</time_frame>
        <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PRP Concentrations</title>
          <description>The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. Concentrations are given as Geometric Mean Concentrations.</description>
          <population>Analysis was performed on the Primary ATP Cohort for Immunogenicity (post-Dose 2 and post-Dose 3), the ATP Cohort for Persistence (pre-Dose 4) and the Fourth Dose ATP Cohort for Immunogenicity (post-Dose 4), including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Microgram per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-dose 2 (N= 280; 94; 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.320" lower_limit="1.097" upper_limit="1.588"/>
                    <measurement group_id="O2" value="0.788" lower_limit="0.571" upper_limit="1.089"/>
                    <measurement group_id="O3" value="0.861" lower_limit="0.607" upper_limit="1.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 3 (N= 265; 88; 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.551" lower_limit="7.502" upper_limit="9.746"/>
                    <measurement group_id="O2" value="3.692" lower_limit="2.747" upper_limit="4.961"/>
                    <measurement group_id="O3" value="5.014" lower_limit="3.675" upper_limit="6.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose 4 (N= 562; 189; 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.175" lower_limit="1.061" upper_limit="1.300"/>
                    <measurement group_id="O2" value="0.668" lower_limit="0.544" upper_limit="0.820"/>
                    <measurement group_id="O3" value="0.748" lower_limit="0.611" upper_limit="0.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose 4 (N= 549; 185; 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.890" lower_limit="31.687" upper_limit="38.417"/>
                    <measurement group_id="O2" value="13.442" lower_limit="11.057" upper_limit="16.343"/>
                    <measurement group_id="O3" value="20.975" lower_limit="17.668" upper_limit="24.899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-measles Concentration Greater Than or Equal to 150 mIU/mL</title>
        <description>The cut-off value assessed was 150 mIU/mL.</description>
        <time_frame>Just prior to the fourth dose and 42 days after the fourth dose</time_frame>
        <population>Analysis was performed on the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-measles Concentration Greater Than or Equal to 150 mIU/mL</title>
          <description>The cut-off value assessed was 150 mIU/mL.</description>
          <population>Analysis was performed on the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="542"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Just prior to the fourth dose (N= 513; 174; 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 days after the fourth dose (N= 542; 185; 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="510"/>
                    <measurement group_id="O2" value="173"/>
                    <measurement group_id="O3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-mumps Titer Greater Than or Equal to 24 ED50</title>
        <description>ED50 is defined as the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent.</description>
        <time_frame>Just prior to the fourth dose and 42 days after the fourth dose</time_frame>
        <population>Analysis was performed on the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-mumps Titer Greater Than or Equal to 24 ED50</title>
          <description>ED50 is defined as the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent.</description>
          <population>Analysis was performed on the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Just prior to the fourth dose (N= 494; 165; 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 days after the fourth dose (N= 509; 170; 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="505"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-rubella Concentration Greater Than or Equal to 4 IU/mL</title>
        <description>The cut-off value assessed was 4 IU/mL.</description>
        <time_frame>Just prior to the fourth dose and 42 days after the fourth dose</time_frame>
        <population>Analysis was performed on the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-rubella Concentration Greater Than or Equal to 4 IU/mL</title>
          <description>The cut-off value assessed was 4 IU/mL.</description>
          <population>Analysis was performed on the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="540"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Just prior to the fourth dose (N= 516; 175; 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 days after the fourth dose (N= 540; 185; 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="540"/>
                    <measurement group_id="O2" value="184"/>
                    <measurement group_id="O3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-varicella Titer Greater Than or Equal to 1:5</title>
        <description>The cut-off value assessed was a titer of 1:5.</description>
        <time_frame>Just prior to the fourth dose and 42 days after the fourth dose</time_frame>
        <population>Analysis was performed on the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-varicella Titer Greater Than or Equal to 1:5</title>
          <description>The cut-off value assessed was a titer of 1:5.</description>
          <population>Analysis was performed on the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="548"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Just prior to the fourth dose (N= 533; 181; 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 days after the fourth dose (N= 548; 184; 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="547"/>
                    <measurement group_id="O2" value="183"/>
                    <measurement group_id="O3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Fourth Dose Response for hSBA-MenC</title>
        <description>Fourth dose response for hSBA-MenC is defined as: •For initially seronegative subjects (i.e., subjects with pre fourth dose hSBA antibody titer below 1:4), post fourth dose hSBA antibody titer greater than or equal to 1:16; •For initially seropositive subjects (i.e., subjects with pre fourth dose antibody titer greater than or equal to 1:4), post fourth dose hSBA antibody titer greater than or equal to 1:128.</description>
        <time_frame>42 days after the fourth dose</time_frame>
        <population>Analysis was performed on the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Fourth Dose Response for hSBA-MenC</title>
          <description>Fourth dose response for hSBA-MenC is defined as: •For initially seronegative subjects (i.e., subjects with pre fourth dose hSBA antibody titer below 1:4), post fourth dose hSBA antibody titer greater than or equal to 1:16; •For initially seropositive subjects (i.e., subjects with pre fourth dose antibody titer greater than or equal to 1:4), post fourth dose hSBA antibody titer greater than or equal to 1:128.</description>
          <population>Analysis was performed on the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Fourth Dose Response for hSBA-MenY</title>
        <description>Fourth dose response for hSBA-MenY defined as: •For initially seronegative subjects (i.e., pre fourth dose hSBA antibody titer &lt; 1:4), post fourth dose hSBA antibody titer greater than or equal to (≥) 1:16; •For initially seropositive subjects with pre fourth dose hSBA antibody titer ≥ 1:4 and &lt; 1:64, post fourth dose hSBA antibody titer at least 4-fold higher than the pre fourth dose hSBA antibody titer; •For initially seropositive subjects with pre fourth dose hSBA antibody titer ≥ 1:64, post fourth dose hSBA antibody titer at least 2-fold higher than the pre fourth dose hSBA antibody titer.</description>
        <time_frame>42 days after the fourth dose</time_frame>
        <population>Analysis was performed on the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Fourth Dose Response for hSBA-MenY</title>
          <description>Fourth dose response for hSBA-MenY defined as: •For initially seronegative subjects (i.e., pre fourth dose hSBA antibody titer &lt; 1:4), post fourth dose hSBA antibody titer greater than or equal to (≥) 1:16; •For initially seropositive subjects with pre fourth dose hSBA antibody titer ≥ 1:4 and &lt; 1:64, post fourth dose hSBA antibody titer at least 4-fold higher than the pre fourth dose hSBA antibody titer; •For initially seropositive subjects with pre fourth dose hSBA antibody titer ≥ 1:64, post fourth dose hSBA antibody titer at least 2-fold higher than the pre fourth dose hSBA antibody titer.</description>
          <population>Analysis was performed on the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-measles Concentration Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects</title>
        <description>The pre-defined cut-off values were 150 mIU/mL and 200 mIU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-measles concentration below 150 mIU/mL.</description>
        <time_frame>42 days after the fourth dose</time_frame>
        <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-measles Concentration Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects</title>
          <description>The pre-defined cut-off values were 150 mIU/mL and 200 mIU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-measles concentration below 150 mIU/mL.</description>
          <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Greater than or equal to 150 mIU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="469"/>
                    <measurement group_id="O2" value="164"/>
                    <measurement group_id="O3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to 200 mIU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-measles Concentrations in Initially Seronegative Subjects</title>
        <description>Concentrations are presented as Geometric Mean Concentrations expressed as mIU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-measles concentration below 150 mIU/mL.</description>
        <time_frame>42 days after the fourth dose</time_frame>
        <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-measles Concentrations in Initially Seronegative Subjects</title>
          <description>Concentrations are presented as Geometric Mean Concentrations expressed as mIU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-measles concentration below 150 mIU/mL.</description>
          <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Milli-International Units per Milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1627.494" lower_limit="1469.996" upper_limit="1801.866"/>
                    <measurement group_id="O2" value="1773.293" lower_limit="1500.779" upper_limit="2095.292"/>
                    <measurement group_id="O3" value="1786.404" lower_limit="1523.083" upper_limit="2095.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-rubella Concentration Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects</title>
        <description>The pre-defined cut-off values were 4 IU/mL and 10 IU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-measles concentration below 4 IU/mL.</description>
        <time_frame>42 days after the fourth dose</time_frame>
        <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-rubella Concentration Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects</title>
          <description>The pre-defined cut-off values were 4 IU/mL and 10 IU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-measles concentration below 4 IU/mL.</description>
          <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 4 International Units per Milliliter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500"/>
                    <measurement group_id="O2" value="174"/>
                    <measurement group_id="O3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 10 International Units per Milliliter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="498"/>
                    <measurement group_id="O2" value="173"/>
                    <measurement group_id="O3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-rubella Concentrations in Initially Seronegative Subjects</title>
        <description>Concentrations are presented as Geometric Mean Concentrations expressed as IU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-rubella concentration below 4 IU/mL.</description>
        <time_frame>42 days after the fourth dose</time_frame>
        <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-rubella Concentrations in Initially Seronegative Subjects</title>
          <description>Concentrations are presented as Geometric Mean Concentrations expressed as IU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-rubella concentration below 4 IU/mL.</description>
          <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>International Units per Milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.779" lower_limit="73.941" upper_limit="83.932"/>
                    <measurement group_id="O2" value="83.168" lower_limit="74.535" upper_limit="92.801"/>
                    <measurement group_id="O3" value="76.691" lower_limit="69.019" upper_limit="85.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-mumps Titer Greater Than or Equal to 28 ED50 in Subjects With Anti-mumps Titer Below 28 ED50 Before Vaccination</title>
        <description>ED50 is defined as the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent.</description>
        <time_frame>42 days after the fourth dose</time_frame>
        <population>Analysis was performed on subjects with a pre-vaccination anti-mumps titer below 28 ED50 in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-mumps Titer Greater Than or Equal to 28 ED50 in Subjects With Anti-mumps Titer Below 28 ED50 Before Vaccination</title>
          <description>ED50 is defined as the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent.</description>
          <population>Analysis was performed on subjects with a pre-vaccination anti-mumps titer below 28 ED50 in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-mumps Titer Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects</title>
        <description>The pre-defined cut-off values were 28 ED50 and 51 ED50. Initially seronegative subjects are defined as subjects with pre-vaccination anti-mumps titer below 24 ED50.</description>
        <time_frame>42 days after the fourth dose</time_frame>
        <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-mumps Titer Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects</title>
          <description>The pre-defined cut-off values were 28 ED50 and 51 ED50. Initially seronegative subjects are defined as subjects with pre-vaccination anti-mumps titer below 24 ED50.</description>
          <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Greater than or equal to 28 ED50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to 51 ED50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-mumps Titers in Initially Seronegative Subjects</title>
        <description>Titers are presented as Geometric Mean Titers expressed as ED50, the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent. Initially seronegative subjects are defined as subjects with pre-vaccination anti-mumps titer below 24 ED50.</description>
        <time_frame>42 days after the fourth dose</time_frame>
        <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-mumps Titers in Initially Seronegative Subjects</title>
          <description>Titers are presented as Geometric Mean Titers expressed as ED50, the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent. Initially seronegative subjects are defined as subjects with pre-vaccination anti-mumps titer below 24 ED50.</description>
          <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.777" lower_limit="111.967" upper_limit="130.281"/>
                    <measurement group_id="O2" value="145.405" lower_limit="128.318" upper_limit="164.766"/>
                    <measurement group_id="O3" value="115.279" lower_limit="101.835" upper_limit="130.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-varicella Titer Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects</title>
        <description>The pre-defined cut-off values were 1:5 and 1:40. Initially seronegative subjects are defined as subjects with pre-vaccination anti-varicella titer below 1:5.</description>
        <time_frame>42 days after the fourth dose</time_frame>
        <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-varicella Titer Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects</title>
          <description>The pre-defined cut-off values were 1:5 and 1:40. Initially seronegative subjects are defined as subjects with pre-vaccination anti-varicella titer below 1:5.</description>
          <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Titer greater than or equal to 1:5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Titer greater than or equal to 1:40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-varicella Titers in Initially Seronegative Subjects</title>
        <description>Titers are presented as Geometric Mean Titers. Initially seronegative subjects are defined as subjects with pre-vaccination anti-varicella titer below 1:5.</description>
        <time_frame>42 days after the fourth dose</time_frame>
        <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-varicella Titers in Initially Seronegative Subjects</title>
          <description>Titers are presented as Geometric Mean Titers. Initially seronegative subjects are defined as subjects with pre-vaccination anti-varicella titer below 1:5.</description>
          <population>Analysis was performed on initially seronegative subjects in the Fourth Dose ATP Cohort for Immunogenicity, including all evaluable subjects with assay result available for the considered time point.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414.633" lower_limit="391.361" upper_limit="439.288"/>
                    <measurement group_id="O2" value="468.985" lower_limit="421.845" upper_limit="521.393"/>
                    <measurement group_id="O3" value="438.280" lower_limit="394.261" upper_limit="487.214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and General Symptoms During the Primary Vaccination Phase</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever (rectal temperature greater than or equal to 38 degrees Celcius), irritability and loss of appetite.</description>
        <time_frame>During a 4-day period (Day 0-3) after any vaccine dose in the primary vaccination phase</time_frame>
        <population>Analysis was performed on all subjects with an available symptom sheet in the Primary Total Vaccinated Cohort, including all subjects vaccinated during the primary vaccination phase.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and General Symptoms During the Primary Vaccination Phase</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever (rectal temperature greater than or equal to 38 degrees Celcius), irritability and loss of appetite.</description>
          <population>Analysis was performed on all subjects with an available symptom sheet in the Primary Total Vaccinated Cohort, including all subjects vaccinated during the primary vaccination phase.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="659"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="432"/>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="556"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="492"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="530"/>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616"/>
                    <measurement group_id="O2" value="211"/>
                    <measurement group_id="O3" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and General Symptoms During the Fourth Dose Vaccination Phase</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever (rectal temperature greater than or equal to 38 degrees Celcius), irritability and loss of appetite.</description>
        <time_frame>During a 4-day period (Day 0-3) after the fourth dose vaccination phase</time_frame>
        <population>Analysis was performed on all subjects with an available symptom sheet in the Fourth Dose Total Vaccinated Cohort, including all subjects vaccinated during the fourth dose vaccination phase.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and General Symptoms During the Fourth Dose Vaccination Phase</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever (rectal temperature greater than or equal to 38 degrees Celcius), irritability and loss of appetite.</description>
          <population>Analysis was performed on all subjects with an available symptom sheet in the Fourth Dose Total Vaccinated Cohort, including all subjects vaccinated during the fourth dose vaccination phase.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="622"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
        <description>Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>During the 31-day (Day 0-30) post-primary and post-fourth dose vaccination period</time_frame>
        <population>Analysis was performed on the Primary Total Vaccinated Cohort and the Fourth Dose Total Vaccinated Cohort, including all subjects vaccinated during the primary and fourth dose vaccination phases, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
          <description>Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>Analysis was performed on the Primary Total Vaccinated Cohort and the Fourth Dose Total Vaccinated Cohort, including all subjects vaccinated during the primary and fourth dose vaccination phases, respectively.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="661"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-primary vaccination period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490"/>
                    <measurement group_id="O2" value="166"/>
                    <measurement group_id="O3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-fourth dose vaccination period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429"/>
                    <measurement group_id="O2" value="139"/>
                    <measurement group_id="O3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Specific Solicited General AEs Related to Measles, Mumps, Rubella Vaccine and Varicella Vaccine</title>
        <description>Specific solicited general symptoms assessed include fever (temperature greater than or equal to 38 degrees Celcius), meningismus/ febrile convulsion, parotid / salivary gland swelling and rash.</description>
        <time_frame>During a 43-day (Day 0-42) after the fourth dose</time_frame>
        <population>Analysis was performed on the Primary Total Vaccinated Cohort and the Fourth Dose Total Vaccinated Cohort, including all subjects vaccinated during the primary and fourth dose vaccination phases, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Specific Solicited General AEs Related to Measles, Mumps, Rubella Vaccine and Varicella Vaccine</title>
          <description>Specific solicited general symptoms assessed include fever (temperature greater than or equal to 38 degrees Celcius), meningismus/ febrile convulsion, parotid / salivary gland swelling and rash.</description>
          <population>Analysis was performed on the Primary Total Vaccinated Cohort and the Fourth Dose Total Vaccinated Cohort, including all subjects vaccinated during the primary and fourth dose vaccination phases, respectively.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="622"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningismus/ febrile convulsion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid / salivary gland swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs), New Onset of Chronic Illnesses (NOCI), Rash, Emergency Room Visits (ER), Physician Office Visits (PO) During the Primary Vaccination Phase</title>
        <description>SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. NOCI: e.g. autoimmune disorders, asthma, type I diabetes and allergies. Types of rash: hives, idiopathic thrombocytopenic purpura and petechiae. ER and PO visits assessed were not related to well-child care, vaccination, injury or common acute illnesses such as upper respiratory tract infection, otitis media, pharyngitis and gastroenteritis.</description>
        <time_frame>From enrolment through the day preceding the fourth dose</time_frame>
        <population>Analysis was performed on the Primary Total Vaccinated Cohort, including all subjects vaccinated during the primary vaccination phase.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs), New Onset of Chronic Illnesses (NOCI), Rash, Emergency Room Visits (ER), Physician Office Visits (PO) During the Primary Vaccination Phase</title>
          <description>SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. NOCI: e.g. autoimmune disorders, asthma, type I diabetes and allergies. Types of rash: hives, idiopathic thrombocytopenic purpura and petechiae. ER and PO visits assessed were not related to well-child care, vaccination, injury or common acute illnesses such as upper respiratory tract infection, otitis media, pharyngitis and gastroenteritis.</description>
          <population>Analysis was performed on the Primary Total Vaccinated Cohort, including all subjects vaccinated during the primary vaccination phase.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="661"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New onset of chronic illnesses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency room visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician office visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs), New Onset of Chronic Illnesses (NOCI), Rash, Emergency Room Visits (ER), Physician Office Visits (PO) During the Fourth Dose Vaccination Phase</title>
        <description>SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. NOCI: e.g. autoimmune disorders, asthma, type I diabetes and allergies. Types of rash: hives, idiopathic thrombocytopenic purpura and petechiae. ER and PO visits assessed were not related to well-child care, vaccination, injury or common acute illnesses such as upper respiratory tract infection, otitis media, pharyngitis and gastroenteritis.</description>
        <time_frame>From the day of administration of the fourth dose until the end of the extended safety follow-up period (last study contact at 18-21 months of age</time_frame>
        <population>Analysis was performed on the Fourth Dose Total Vaccinated Cohort, including all subjects vaccinated during the ourth dose vaccination phase.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB + Meningitec Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
          <group group_id="O3">
            <title>ActHIB/PedvaxHIB Group</title>
            <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs), New Onset of Chronic Illnesses (NOCI), Rash, Emergency Room Visits (ER), Physician Office Visits (PO) During the Fourth Dose Vaccination Phase</title>
          <description>SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. NOCI: e.g. autoimmune disorders, asthma, type I diabetes and allergies. Types of rash: hives, idiopathic thrombocytopenic purpura and petechiae. ER and PO visits assessed were not related to well-child care, vaccination, injury or common acute illnesses such as upper respiratory tract infection, otitis media, pharyngitis and gastroenteritis.</description>
          <population>Analysis was performed on the Fourth Dose Total Vaccinated Cohort, including all subjects vaccinated during the ourth dose vaccination phase.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="625"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New onset of chronic illnesses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency room visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician office visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events (SAEs): From Day 0 up to 18-21 months of age; Non-systematically assessed frequent AEs: Day 0-30 post-primary and post-fourth dose; Systematically assessed frequent AEs: Day 0-3 post-primary and post-fourth dose vaccination phase.</time_frame>
      <desc>SAEs and non-systematically assessed frequent AEs were assessed on the Primary &amp; Fourth dose Total Vaccinated Cohort, respectively. Systematically assessed frequent AEs were assessed on respectively subjects from the Primary and Fourth dose Total Vaccinated Cohort who returned their symptom sheet.</desc>
      <group_list>
        <group group_id="E1">
          <title>MenHibrix Group</title>
          <description>Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
        </group>
        <group group_id="E2">
          <title>ActHIB + Meningitec Group</title>
          <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
        </group>
        <group group_id="E3">
          <title>ActHIB/PedvaxHIB Group</title>
          <description>Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cyanosis</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Respiratory tract malformation</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Oesophageal rupture</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigation</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint effusion</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypotonic-hyporesponsive episode</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Infantile spasms</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="616" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="212" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Teething</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at the injection site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="432" subjects_at_risk="658"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="152" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Redness at the injection site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="556" subjects_at_risk="658"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="189" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Swelling at the injection site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="492" subjects_at_risk="658"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="167" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pain at the injection site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Redness at the injection site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="379" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Swelling at the injection site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="225" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="530" subjects_at_risk="659"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="176" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="659"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="616" subjects_at_risk="659"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="212" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="410" subjects_at_risk="659"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="135" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="361" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="224" subjects_at_risk="622"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Post-fourth dose vaccination phase</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Post-primary vaccination phase</description>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

